Seronegative Lyme neuroborreliosis in a patient treated by rituximab

Rev Neurol (Paris). 2016 Feb;172(2):166-7. doi: 10.1016/j.neurol.2015.06.009. Epub 2015 Aug 28.

Authors

F Gampourou¹, F Taithe², X Moisset², P Clavelou²

Affiliations

¹ Service de neurologie, Clermont université, université d'Auvergne, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France. Electronic address: fanfan_le_carabin@hotmail.com.
² Service de neurologie, Clermont université, université d'Auvergne, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France.

PMID: 26318890
DOI: 10.1016/j.neurol.2015.06.009

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use
Borrelia burgdorferi Group / immunology
Borrelia burgdorferi Group / isolation & purification*
Cyclophosphamide / administration & dosage
Female
Humans
Immunocompromised Host / drug effects
Lyme Neuroborreliosis / blood
Lyme Neuroborreliosis / complications
Lyme Neuroborreliosis / diagnosis*
Lymphoma, Follicular / drug therapy
Middle Aged
Paresis / diagnosis
Paresis / microbiology
Rituximab / administration & dosage
Rituximab / therapeutic use*
Vincristine / administration & dosage

Substances

Antineoplastic Agents
Rituximab
Vincristine
Cyclophosphamide